Peanut Allergen Threshold Study (PATS): validation of eliciting doses using a novel single-dose challenge protocol

Allergy, Asthma & Clinical Immunology

Giovanni A Zurzolo¹  Katrina J Allen²  Steve L Taylor⁵  Wayne G Shreffler³  Joseph L Baumert⁵  Mimi L K Tang²  Lyle C Gurrin⁶  Michael L Mathai¹  Julie A Nordlee⁵  Audrey DunnGalvin⁴  Jonathan O’B Hourihane⁴ 

[1] Biomedical and Lifestyle Diseases Unit, School of Biomedical and Health Sciences, Victoria University, Melbourne, Australia

[2] University of Melbourne Department of Paediatrics, Melbourne, Australia

[3] Food Allergy Centre and the Centre for Immunology and Inflammatory Disease, Massachusetts General Hospital/Harvard Medical School, Boston, USA

[4] Paediatrics and Child Health, University College, Cork, Ireland

[5] Food Allergy Research and Resource Program, University of Nebraska, Lincoln, Nebraska

[6] Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia

关键词: Peanut Allergen Threshold Study (PATS);    Voluntary Incidental Trace Allergen Labelling (VITAL);    Oral Food Challenges (OFC);    Peanut thresholds;    Single dose;    Food Allergy related Quality of Life Questionnaires-(FAQLQ);    Eliciting dose (ED);   

Others  :  792157
DOI  :  10.1186/1710-1492-9-35

 received in 2013-06-06, accepted in 2013-08-14,  发布年份 2013

【 摘 要 】

Background

The eliciting dose (ED) for a peanut allergic reaction in 5% of the peanut allergic population, the ED05, is 1.5 mg of peanut protein. This ED05 was derived from oral food challenges (OFC) that use graded, incremental doses administered at fixed time intervals. Individual patients’ threshold doses were used to generate population dose-distribution curves using probability distributions from which the ED05 was then determined. It is important to clinically validate that this dose is predictive of the allergenic response in a further unselected group of peanut-allergic individuals.

Methods/Aims

This is a multi-centre study involving three national level referral and teaching centres. (Cork University Hospital, Ireland, Royal Children’s Hospital Melbourne, Australia and Massachusetts General Hospital, Boston, U.S.A.) The study is now in process and will continue to run until all centres have recruited 125 participates in each respective centre.

A total of 375 participants, aged 1–18 years will be recruited during routine Allergy appointments in the centres. The aim is to assess the precision of the predicted ED05 using a single dose (6 mg peanut = 1.5 mg of peanut protein) in the form of a cookie. Validated Food Allergy related Quality of Life Questionnaires-(FAQLQ) will be self-administered prior to OFC and 1 month after challenge to assess the impact of a single dose OFC on FAQL. Serological and cell based in vitro studies will be performed.

Conclusion

The validation of the ED05 threshold for allergic reactions in peanut allergic subjects has potential value for public health measures. The single dose OFC, based upon the statistical dose-distribution analysis of past challenge trials, promises an efficient approach to identify the most highly sensitive patients within any given food-allergic population.

【 授权许可】

   
2013 Zurzolo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Allen KJ, Remington BC, Baumert JL, Crevel R, Houben GF, Brooks-Taylor S, et al.: Clinical challenge data for development of allergen management thresholds for precautionary labeling of foods- VITAL 2.0. J Allergy Clin Immun 2013,  . In press
• [2]Taylor SL, Crevel RWR, Sheffield D, Kabourek J, Baumert J: Threshold dose for peanut: risk characterization based upon published results from challenges of peanut-allergic individuals. Food Chem Toxicol 2009, 47(6):1198-1204.
• [3]Taylor SL, Moneret-Vautrin DA, Crevel RWR, Sheffield D, Morisset M, Dumont P, et al.: Threshold dose for peanut: risk characterization based upon diagnostic oral challenge of a series of 286 peanut-allergic individuals. Food Chem Toxicol 2010, 48(3):814-819.
• [4]Zurzolo GA, Mathai ML, Koplin JJ, Allen KJ: Precautionary allergen labelling following new labelling practice in Australia. J Paediatr Child Health 2013, 49(4):E306. E10
• [5]Zurzolo G, Koplin J, Mathai M, Mimi T, Allen K: Perceptions of precautionary labelling among parents of children with food allergy and anaphylaxis. Med J Aust 2013, 198(11):621-623. Epub 2013/08/08
• [6]Allergen, Bureau: Summary of the VITAL scientific expert panel recommendations. 2011. Available from: http://www.allergenbureau.net/downloads/vital/VSEP-Summary-Report-Oct-2011.pdf webcite
• [7]Madsen CB, Hattersley S, Allen KJ, Beyer K, Chan CH, Godefroy SB, et al.: Can we define a tolerable level of risk in food allergy? Report from a EuroPrevall/UK Food Standards Agency workshop. Clinical & Experimental Allergy 2012, 42(1):30-37. n/a-n/a
• [8]Osborne NJ, Koplin JJ, Martin PE, Gurrin LC, Thiele L, Tang ML, et al.: The HealthNuts population-based study of paediatric food allergy: validity, safety and acceptability. Clinical & Experimental Allergy 2010, 40(10):1516-1522.
• [9]Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, et al.: Standardizing double-blind, placebo-controlled oral food challenges: American academy of allergy, asthma and immunology–European academy of allergy and clinical immunology PRACTALL consensus report. J Allergy Clin Immun 2012, 130(6):1260-1274.
• [10]Koplin JJ, Tang MLK, Martin PE, Osborne NJ, Lowe AJ, Ponsonby A-L, et al.: Predetermined challenge eligibility and cessation criteria for oral food challenges in the HealthNuts population-based study of infants. J Allergy Clin Immun 2012, 129(4):1145-1147.
• [11]DunnGalvin A, Hourihane JB: Developmental Aspects of Health Related Quality of Life (HRQL) in Food Related Chronic Disease: the example of food allergy. In Handbook of Behavior, Food and Nutrition. Edited by Preedy VR, Watson RR, Martin CR. New York: Springer; 2011:3077-3098.
• [12]DunnGalvin A, Hourihane JOB: Chapter 3 developmental trajectories in food allergy: a review. In Advances in food and nutrition research. Edited by Steve LT. Waltham, Massachusetts, USA: Academic Press; 2009:65-100.
• [13]Kruizinga AG, Briggs D, Crevel RWR, Knulst AC, Bosch LMC, Houben GF: Probabilistic risk assessment model for allergens in food: sensitivity analysis of the minimum eliciting dose and food consumption. Food Chem Toxicol 2008, 46(5):1437-1443.
• [14]Madsen CB, Hattersley S, Buck J, Gendel SM, Houben GF, Hourihane JOB, et al.: Approaches to risk assessment in food allergy: report from a workshop “developing a framework for assessing the risk from allergenic foods”. Food Chem Toxicol 2009, 47(2):480-489.
• [15]Mills ENC, Valovirta E, Madsen C, Taylor SL, Vieths S, Anklam E, et al.: Information provision for allergic consumers – where are we going with food allergen labelling? Allergy 2004, 59(12):1262-1268.
• [16]Marklund B, Wilde-Larsson B, Ahlstedt S, Nordstrom G: Adolescents’ experiences of being food-hypersensitive: a qualitative study. BMC Nurs 2007, 6:8. Epub 2007/10/10 BioMed Central Full Text
• [17]Hourihane JOB, Bedwani SJ, Dean TP, Warner JO: Randomised, double blind, crossover challenge study of allergenicity of peanut oils in subjects allergic to peanuts. BMJ 1997, 314(7087):1084.
• [18]Madsen CB, Crevel R, Chan C-H, Dubois AEJ, DunnGalvin A, Flokstra-de Blok BMJ, et al.: Food allergy: stakeholder perspectives on acceptable risk. Regul Toxicol Pharmacol 2012, 57(2–3):256-265.
• [19]DunnGalvin A, Cullinane C, Daly DA, Flokstra-de Blok BMJ, Dubois AEJ, Hourihane JOB: Longitudinal validity and responsiveness of the Food Allergy Quality of Life Questionnaire – Parent Form in children 0–12 years following positive and negative food challenges. Clinical & Experimental Allergy 2010, 40(3):476-485.
• [20]DunnGalvin A, Gaffney A, Hourihane JOB: Developmental pathways in food allergy: a new theoretical framework. Allergy 2009, 64(4):560-568.
• [21]DunnGalvin A, Hourihane JOB: Self-assessment of reaction thresholds in food allergy: a new theory of risk taking which changes over time. J Allergy Clin Immun 2009, 123(2):S142.